Irodalom
Adjuváns kezelés
Adjuvant therapy in pancreatic cancer: Phase I trial of radiation dose
escalation with concurrent full-dose gemcitabine.
Allen AM, Zalupski MM, Robertson JM, Eckhauser FE, Simone D, Brown D, Hejna G,
Normolle D, Lawrence TS, McGinn CJ.
Int J Radiat Oncol Biol Phys. 2004 Aug 1;59(5):1461-7.
Clinical overview: adjuvant therapy of gastrointestinal cancer.
Macdonald JS.
Cancer Chemother Pharmacol. 2004 Aug 7;
Conclusions from the European Study Group for Pancreatic Cancer adjuvant trial
of chemoradiotherapy and chemotherapy for pancreatic cancer.
Ghaneh P, Neoptolemos JP.
Surg Oncol Clin N Am. 2004 Oct;13(4):567-87, vii-viii.
Role of postoperative adjuvant chemotherapy with gemcitabine for pancreatic cancer:
feasibility and anti-tumor effect
Kurosaki I, Tsuchiya Y, Shimizu T, Hatakeyama K.
Gan To Kagaku Ryoho. 2004 Aug;31(8):1201-4.
Adjuvant radiochemotherapy for pancreatic cancer–why we might need it even
more.
Fleckenstein J, Rube C.
Front Radiat Ther Oncol. 2004;38:82-6.
Adjuvant radiochemotherapy in pancreatic cancer: contra.
Henne-Bruns D, Staib L.
Front Radiat Ther Oncol. 2004;38:76-81.
Phase I study of a MUC1 vaccine composed of different doses of MUC1 peptide with SBAS2
adjuvant in resected and locally advanced pancreatic cancer.
Ramanathan RK, Lee KM, McKolanis J, Hitbold E, Schraut W, Moser AJ, Warnick E,
Whiteside T, Osborne J, Kim H, Day R, Troetschel M, Finn OJ.
Cancer Immunol Immunother. 2004 Sep 14;
The evolving role of postoperative adjuvant radiation therapy for pancreatic cancer.
Garofalo MC, Kwok Y, Regine WF.
Surg Oncol Clin N Am. 2004 Oct;13(4):589-604, viii.
Adjuvant therapy in pancreatic cancer: Phase I trial of radiation dose
escalation with concurrent full-dose gemcitabine.
Allen AM, Zalupski MM, Robertson JM, Eckhauser FE, Simone D, Brown D, Hejna G,
Normolle D, Lawrence TS, McGinn CJ.
Int J Radiat Oncol Biol Phys. 2004 Aug 1;59(5):1461-7.
Adjuvant radiochemotherapy for pancreatic cancer–why we might need it even
more.
Fleckenstein J, Rube C.
Front Radiat Ther Oncol. 2004;38:82-6.
Adjuvant radiochemotherapy in pancreatic cancer: contra.
Henne-Bruns D, Staib L.
Front Radiat Ther Oncol. 2004;38:76-81.
Adjuvant therapy for pancreatic cancer: current status and future directions.
Xiong HQ, Abbruzzese JL.
Surg Oncol Clin N Am. 2004 Oct;13(4):737-49, xi.
The evolution of adjuvant and neoadjuvant chemotherapy and radiation for
advanced pancreatic cancer: from 5-fluorouracil to GTX.
Fogelman DR, Chen J, Chabot JA, Allendorf JD, Schrope BA, Ennis RD, Schreibman
SM, Fine RL.
Surg Oncol Clin N Am. 2004 Oct;13(4):711-35, x.
Survival efficacy of adjuvant cytosine-analogue CS-682 in a fluorescent
orthotopic model of human pancreatic cancer.
Katz MH, Bouvet M, Takimoto S, Spivack D, Moossa AR, Hoffman RM.
Cancer Res. 2004 Mar 1;64(5):1828-33.
Terminally modified oligodeoxynucleotides directed against p53 in an orthotopic
xenograft model: a novel adjuvant treatment strategy for pancreatic ductal
carcinoma.
Tepel J, Kruse ML, March C, Fiedler A, Kapischke M, Ketterer T, Sipos B, Kremer
B, Kalthoff H.
Pancreas. 2004 Jan;28(1):1-12.
Neoadjuvans kezelés
Neoadjuvant therapy for resectable pancreatic cancer.
Raut CP, Evans DB, Crane CH, Pisters PW, Wolff RA.
Surg Oncol Clin N Am. 2004 Oct;13(4):639-61, ix. Review.
Neoadjuvant therapy for pancreatic cancer: the Duke experience.
White RR, Tyler DS.
Surg Oncol Clin N Am. 2004 Oct;13(4):675-84, ix-x. Review.
Neoadjuvant induction chemotherapy followed by chemoradiation: a phase I trial of
gemcitabine, cisplatin, and 5-fluorouracil for advanced pancreatic/gastrointestinal
malignancies.
Staley CA, Harris WB, Landry J, Small W, Kooby D, Gillespie TW, Meyers M, Bhalla KN.
Surg Oncol Clin N Am. 2004 Oct;13(4):697-709, x.
The evolution of adjuvant and neoadjuvant chemotherapy and radiation for advanced
pancreatic cancer: from 5-fluorouracil to GTX.
Fogelman DR, Chen J, Chabot JA, Allendorf JD, Schrope BA, Ennis RD, Schreibman SM,
Fine RL.
Surg Oncol Clin N Am. 2004 Oct;13(4):711-35, x. Review.
Assessment of pathologic response after preoperative chemoradiotherapy and
surgery in pancreatic adenocarcinoma.
Moutardier V, Magnin V, Turrini O, Viret F, Hennekinne-Mucci S, Goncalves A,Pesenti C,
Guiramand J, Lelong B, Giovannini M, Monges G, Houvenaeghel G,
Delpero JR.
Int J Radiat Oncol Biol Phys. 2004 Oct 1;60(2):437-43.
Neoadjuvant induction chemotherapy followed by chemoradiation: a phase I trial of
gemcitabine, cisplatin, and 5-fluorouracil for advanced
pancreatic/gastrointestinal malignancies.
Staley CA, Harris WB, Landry J, Small W, Kooby D, Gillespie TW, Meyers M, Bhalla KN.
Surg Oncol Clin N Am. 2004 Oct;13(4):697-709, x.
Complete pathologic responses to preoperative chemoradiation in two patients with
adenocarcinoma of the pancreas.
Magnin V, Viret F, Moutardier V, Lelong B, Giovannini M, Monges G, Delpero JR.
Pancreas. 2004 Jan;28(1):103-4.
Adjuvant chemotherapy for unresectable locally advanced pancreatic cancer in light of its
characteristics
Taoka H, Hirano H, Mitsui Y, Umino W, Nobuoka Y, Yamashita M, Tanigawa K,
Yoshimine S, Imai T, Kadowaki S, Miyashita K, Ikuma H, Nakamura T, Murata T.
Gan To Kagaku Ryoho. 2004 Sep;31(9):1365-70.
Chemotherápia előrehaladott daganatban
Phase II study of gemcitabine combined with uracil-tegafur in metastatic
pancreatic cancer.
Lee J, Park JO, Kim WS, Lee SI, Song SY, Lim do H, Choi SH, Heo JS, Lee KT, Lee
JK, Kim K, Jung CW, Im YH, Lee MH, Kang WK, Park K.
Oncology. 2004;66(1):32-7.
Randomized phase II study evaluating oxaliplatin alone, oxaliplatin combined
with infusional 5-FU, and infusional 5-FU alone in advanced pancreatic carcinoma
patients.
Ducreux M, Mitry E, Ould-Kaci M, Boige V, Seitz JF, Bugat R, Breau JL, Bouche O,
Etienne PL, Tigaud JM, Morvan F, Cvitkovic E, Rougier P.
Ann Oncol. 2004 Mar;15(3):467-73.
Weekly high-dose 5-fluorouracil and folinic acid in metastatic pancreatic
carcinoma: a phase II study of the EORTC GastroIntestinal Tract Cancer
Cooperative Group.
Van Rijswijk RE, Jeziorski K, Wagener DJ, Van Laethem JL, Reuse S, Baron B, Wils
J; EORTC GastroIntestinal Tract Cancer Cooperative Group.
Eur J Cancer. 2004 Sep;40(14):2077-81.
Gemcitabine and mitomycin C in advanced pancreatic cancer: a single-institution
experience.
Tuinmann G, Hegewisch-Becker S, Zschaber R, Kehr A, Schulz J, Hossfeld DK.
Anticancer Drugs. 2004 Jul;15(6):575-9
Potent chemopreventive agents against pancreatic cancer.
Nishikawa A, Furukawa F, Lee IS, Tanaka T, Hirose M.
Curr Cancer Drug Targets. 2004 Jun;4(4):373-84.
A phase II trial of FUdR in patients with advanced pancreatic cancer.
Ardalan B, Lima M.
J Cancer Res Clin Oncol. 2004 Jul 29;
Phase II study of gemcitabine in combination with docetaxel in patients with
advanced pancreatic carcinoma (E1298). A trial of the eastern cooperative
oncology group.
Shepard RC, Levy DE, Berlin JD, Stuart K, Harris JE, Aviles V, Thomas JP, Benson
AB 3rd.
Oncology. 2004;66(4):303-9.
Hypoxia increases resistance of human pancreatic cancer cells to apoptosis
induced by gemcitabine.
Yokoi K, Fidler IJ.
Clin Cancer Res. 2004 Apr 1;10(7):2299-306
Role of progastrins and gastrins and their receptors in GI and pancreatic
cancers: targets for treatment.
Rengifo-Cam W, Singh P.
Curr Pharm Des. 2004;10(19):2345-58.
Phase I study of gemcitabine (GEM) and UFT combination chemotherapy for
unresectable/recurrent pancreatic cancer
Nakamori S, Tujie M, Takahashi Y, Maruhashi S, Miyamoto A, Nagano H, Dono K,
Umeshita K, Sakon M, Monden M.
Gan To Kagaku Ryoho. 2004 Jan;31(1):51-4.
Resistance of pancreatic cancer to gemcitabine treatment is dependent on
mitochondria-mediated apoptosis.
Schniewind B, Christgen M, Kurdow R, Haye S, Kremer B, Kalthoff H, Ungefroren H.
Int J Cancer. 2004 Mar 20;109(2):182-8.
The proteasome inhibitor bortezomib enhances the activity of docetaxel in
orthotopic human pancreatic tumor xenografts.
Nawrocki ST, Sweeney-Gotsch B, Takamori R, McConkey DJ.
Mol Cancer Ther. 2004 Jan;3(1):59-70.
Mouse models of pancreatic cancer: the fur is finally flying!
Leach SD.
Cancer Cell. 2004 Jan;5(1):7-11.
Antitumor efficacy of intermittent treatment schedules with the rapamycin
derivative RAD001 correlates with prolonged inactivation of ribosomal protein S6
kinase 1 in peripheral blood mononuclear cells.
Boulay A, Zumstein-Mecker S, Stephan C, Beuvink I, Zilbermann F, Haller R,
Tobler S, Heusser C, O’Reilly T, Stolz B, Marti A, Thomas G, Lane HA.
Cancer Res. 2004 Jan 1;64(1):252-61.
EUS-guided photodynamic therapy of the pancreas: a pilot study.
Chan HH, Nishioka NS, Mino M, Lauwers GY, Puricelli WP, Collier KN, Brugge WR.
Gastrointest Endosc. 2004 Jan;59(1):95-9.
An optimal dosing schedule for a novel combination antimetabolite, TAS-102,
based on its intracellular metabolism and its incorporation into DNA.
Emura T, Nakagawa F, Fujioka A, Ohshimo H, Yokogawa T, Okabe H, Kitazato K.
Int J Mol Med. 2004 Feb;13(2):249-55.
Thymidine kinase and thymidine phosphorylase level as the main predictive
parameter for sensitivity to TAS-102 in a mouse model.
Emura T, Nakagawa F, Fujioka A, Ohshimo H, Kitazato K.
Oncol Rep. 2004 Feb;11(2):381-7.
Tumor-stroma interaction of human pancreatic cancer: acquired resistance to
anticancer drugs and proliferation regulation is dependent on extracellular
matrix proteins.
Miyamoto H, Murakami T, Tsuchida K, Sugino H, Miyake H, Tashiro S.
Pancreas. 2004 Jan;28(1):38-44.
Inhibition of pancreatic adenocarcinoma cellular invasiveness by blebbistatin: a
novel myosin II inhibitor.
Duxbury MS, Ashley SW, Whang EE.
Biochem Biophys Res Commun. 2004 Jan 23;313(4):992-7.
The betaII isotype of tubulin is present in the cell nuclei of a variety of
cancers.
Yeh IT, Luduena RF.
Cell Motil Cytoskeleton. 2004 Feb;57(2):96-106.
Phase I trial using a time-to-event continual reassessment strategy for dose
escalation of cisplatin combined with gemcitabine and radiation therapy in
pancreatic cancer.
Muler JH, McGinn CJ, Normolle D, Lawrence T, Brown D, Hejna G, Zalupski MM.
J Clin Oncol. 2004 Jan 15;22(2):238-43. Epub 2003 Dec 09.
RNA interference targeting the M2 subunit of ribonucleotide reductase enhances
pancreatic adenocarcinoma chemosensitivity to gemcitabine.
Duxbury MS, Ito H, Zinner MJ, Ashley SW, Whang EE.
Oncogene. 2004 Feb 26;23(8):1539-48.
First clinical experience using a ‘pathotropic’ injectable retroviral vector
(Rexin-G) as intervention for stage IV pancreatic cancer.
Gordon EM, Cornelio GH, Lorenzo CC 3rd, Levy JP, Reed RA, Liu L, Hall FL.
Int J Oncol. 2004 Jan;24(1):177-85.
A case of unresectable pancreatic cancer showing tumor dormancy treated with
gemcitabine
Egawa T, Nagashima A, Kitano M, Doi M, Hayashi S, Yoshii H.
Gan To Kagaku Ryoho. 2004 Oct;31(11):1932-4.
Synergistic interaction between sphingomyelin and gemcitabine potentiates
ceramide-mediated apoptosis in pancreatic cancer.
Modrak DE, Cardillo TM, Newsome GA, Goldenberg DM, Gold DV.
Cancer Res. 2004 Nov 15;64(22):8405-10.
Researchers optimistic about targeted drugs for pancreatic cancer.
McBride G.
J Natl Cancer Inst. 2004 Nov 3;96(21):1570-2.
Evaluation of antimitotic activity of Rotula aquatica (Lour): a traditional herb
used in treatment of cancer.
Patil S, Narayanan S, Eibl G, Jolly CI.
Indian J Exp Biol. 2004 Sep;42(9):893-9.
Radiochemotherapy in unresectable pancreatic cancer.
Hocht S, Wiegel T, Siegmann A, Hinkelbein W.
Front Radiat Ther Oncol. 2004;38:87-93.
Economic evaluation of gemcitabine in the treatment of pancreatic cancer in the UK. How
important is quality of life?
Bansback N, Ward S, Karnon J.
Eur J Health Econ. 2004 Jun;5(2):188-9.
A case report of metastatic pancreatic cancer that responded remarkably to the
combination of thalidomide, celecoxib and irinotecan
Hada M, Mizutari K.
Gan To Kagaku Ryoho. 2004 Sep;31(9):1407-10
Clinical study of gemcitabine therapy for recurrent or metastatic pancreatic
cancer
Moriwaki T, Hyodo I, Nishina T, Nasu J, Hidaka S, Kajiwara T, Tsuzuki T, Hirao
K, Tsubouchi E, Yamauchi Y, Hirasaki S, Masumoto T, Tanada M.
Gan To Kagaku Ryoho. 2004 Sep;31(9):1373-6.
Intravenous vitamin C as a chemotherapy agent: a report on clinical cases.
Riordan HD, Riordan NH, Jackson JA, Casciari JJ, Hunninghake R, Gonzalez MJ,Mora EM,
Miranda-Massari JR, Rosario N, Rivera A.
P R Health Sci J. 2004 Jun;23(2):115-8.
Clinical trials referral resource. Current phase II and phase III clinical
trials for pancreatic cancer.
Mooney MM, Schoenfeldt M.
Oncology (Huntingt). 2004 Jul;18(8):1008, 1013-4, 1016.
Modern management of pancreatic carcinoma.
Goldstein D, Carroll S, Apte M, Keogh G.
Intern Med J. 2004 Aug;34(8):475-81.
New approaches for pancreatic cancer in Japan.
Okusaka T, Matsumura Y, Aoki K.
Cancer Chemother Pharmacol. 2004 Aug 14;
Gemcitabine combined with infusional 5-fluorouracil and high-dose leucovorin for
the treatment of advanced carcinoma of the pancreas.
Oztop I, Yilmaz U, Yavuzsen T, Yaren A, Tarhan O, Sagol O, Coker A, Alakavuklar
M.
Chemotherapy. 2004 Jun;50(3):127-32.
5-fluorouracil-based chemoradiation in unresectable pancreatic carcinoma: Phase
I-II dose-escalation study.
Morganti AG, Valentini V, Macchia G, Mattiucci GC, Costamagna G, Deodato F,
Smaniotto D, Luzi S, Balducci M, Barbi S, Perri V, Trodella L, Cellini N.
Int J Radiat Oncol Biol Phys. 2004 Aug 1;59(5):1454-60.
Gemcitabine and continuous infusion of 5-fluorouracil in locally advanced and
metastatic pancreatic cancer: a phase I-II study.
Oliani C, Padovani M, Manno P, Barana D, Falconi M, Bassi C, Cavallini G,
Pederzoli P, Cetto GL.
Anticancer Res. 2004 May-Jun;24(3b):2107-12.
A human single-chain antibody specific for integrin alpha3beta1 capable of cell
internalization and delivery of antitumor agents.
Lillo AM, Sun C, Gao C, Ditzel H, Parrish J, Gauss CM, Moss J, Felding-Habermann
B, Wirsching P, Boger DL, Janda KD.
Chem Biol. 2004 Jul;11(7):897-906.
Chemotherapy for pancreatic cancer.
Tsai JY, Nadeem A, Safran H.
Med Health R I. 2004 May;87(5):132-4.
Diagnosis and treatment of malignant pancreatic endocrine tumour.
Wang L, Zhao YP, Lee CI, Liao Q.
Chin Med Sci J. 2004 Jun;19(2):130-3.
Treatment of metastatic pancreatic cancer with a combination of gemcitabine and
5-fluorouracil: a single center phase II study.
Kanat O, Evrensel T, Kurt E, Demiray M, Gonullu G, Arslan M, Manavoglu O.
Tumori. 2004 Mar-Apr;90(2):192-5.
Phase II study of radiotherapy combined with gemcitabine for locally advanced
pancreatic cancer.
Okusaka T, Ito Y, Ueno H, Ikeda M, Takezako Y, Morizane C, Kagami Y, Ikeda H.
Br J Cancer. 2004 Aug 16;91(4):673-7.
Quality of life in patients with gastroenteropancreatic tumors treated with
[177Lu-DOTA0,Tyr3]octreotate.
Teunissen JJ, Kwekkeboom DJ, Krenning EP.
J Clin Oncol. 2004 Jul 1;22(13):2724-9.
A case of advanced pancreatic cancer with remarkable response to thalidomide,
celecoxib and gemcitabine
Hada M, Mizutari K.
Gan To Kagaku Ryoho. 2004 Jun;31(6):959-61.
Two cases of advanced pancreatic cancer responding to gemcitabine with long survival of 2
years
Yajima T, Furukawa Y, Ishii Y, Hattori Y, Matsumoto N, Yamamoto M, Yamaoka Y,
Fujihara M, Fujita M, Kuniki H.
Gan To Kagaku Ryoho. 2004 Jun;31(6):953-7
A case of curatively resected gastric cancer through an effective response to
chemotherapy
Ema T, Arai K, Maeda Y, Iwasaki Y, Katayanagi S, Takahashi K, Yamaguchi T,
Takahashi T.
Gan To Kagaku Ryoho. 2004 Jun;31(6):925-8.
Chemotherapy for pancreatic cancer.
Bydder S, Spry N.
N Engl J Med. 2004 Jun 24;350(26):2713-5; author reply 2713-5.
Chemotherapy for pancreatic cancer.
Crane CH, Ben-Josef E, Small W Jr.
N Engl J Med. 2004 Jun 24;350(26):2713-5; author reply 2713-5.
Chemotherapy for pancreatic cancer.
Morris SL, Beasley M, Leslie M.
N Engl J Med. 2004 Jun 24;350(26):2713-5; author reply 2713-5.
Systemic treatment of pancreatic cancer.
Van Cutsem E, Aerts R, Haustermans K, Topal B, Van Steenbergen W, Verslype C.
Eur J Gastroenterol Hepatol. 2004 Mar;16(3):265-74.
Novel therapies for pancreatic adenocarcinoma.
Pino SM, Xiong HQ, McConkey D, Abbruzzese JL.
Curr Gastroenterol Rep. 2004 Apr;6(2):119-25.
Pancreatic carcinoma with brain metastases: case report and literature review.
El Kamar FG, Jindal K, Grossbard ML, Mizrachi HH, Kozuch PS.
Dig Liver Dis. 2004 May;36(5):355-60.
Renal metastasis from pancreatic adenocarcinoma.
Martino L, Martino F, Coluccio A, Mangiarini MG, Chioda C.
Arch Ital Urol Androl. 2004 Mar;76(1):37-9.
Concurrent chemoradiotherapy using full-dose gemcitabine for patients with
unresectable pancreatic cancer
Yamazaki H, Nishiyama K, Koizumi M.
Nippon Igaku Hoshasen Gakkai Zasshi. 2004 May;64(4):216-9.
Angiogenesis of gastrointestinal tumours and their metastases–a target for
intervention?
Garcea G, Lloyd TD, Gescher A, Dennison AR, Steward WP, Berry DP.
Eur J Cancer. 2004 Jun;40(9):1302-13.
A novel role for carcinoembryonic antigen-related cell adhesion molecule 6 as a
determinant of gemcitabine chemoresistance in pancreatic adenocarcinoma cells.
Duxbury MS, Ito H, Benoit E, Waseem T, Ashley SW, Whang EE.
Cancer Res. 2004 Jun 1;64(11):3987-93
Topotecan in patients with advanced neuroendocrine tumors: a phase II study with
significant hematologic toxicity.
Ansell SM, Mahoney MR, Green EM, Rubin J.
Am J Clin Oncol. 2004 Jun;27(3):232-5.
New chemotherapeutic advances in pancreatic, colorectal, and gastric cancers.
Diaz-Rubio E.
Oncologist. 2004;9(3):282-94.
Best supportive care of pancreatic carcinoma
Schoppmeyer K, Mossner J.
Internist (Berl). 2004 Jul;45(7):769-76.
Survival and clinical outcome of patients with neuroendocrine tumors of the
gastroenteropancreatic tract in a german referral center.
Pape UF, Bohmig M, Berndt U, Tiling N, Wiedenmann B, Plockinger U.
Ann N Y Acad Sci. 2004 Apr;1014:222-33.
Complete remission of metastatic pancreatic cancer with cardiac involvement
after gemcitabine, oxaliplatin and 46-h infusion of 5-fluorouracil/leucovorin.
Wu WC, Chen SC, Su YC, Chuang WL, Chen LT.
J Gastroenterol Hepatol. 2004 Jun;19(6):716-7.
Intensity-modulated radiotherapy in treatment of pancreatic and bile duct
malignancies: toxicity and clinical outcome.
Milano MT, Chmura SJ, Garofalo MC, Rash C, Roeske JC, Connell PP, Kwon OH, Jani
AB, Heimann R.
Int J Radiat Oncol Biol Phys. 2004 Jun 1;59(2):445-53.
Pegylated liposomal doxorubicin in combination with mitomycin C, infusional
5-fluorouracil and sodium folinic acid. A phase-I-study in patients with upper
gastrointestinal cancer.
Hofheinz RD, Willer A, Weisser A, Gnad U, Saussele S, Kreil S, Hartmann JT,
Hehlmann R, Hochhaus A.
Br J Cancer. 2004 May 17;90(10):1893-7.
Synergistic cytotoxicity and pharmacogenetics of gemcitabine and pemetrexed
combination in pancreatic cancer cell lines.
Giovannetti E, Mey V, Danesi R, Mosca I, Del Tacca M.
Clin Cancer Res. 2004 May 1;10(9):2936-43.
A novel synthetic inhibitor of CDC25 phosphatases: BN82002.
Brezak MC, Quaranta M, Mondesert O, Galcera MO, Lavergne O, Alby F, Cazales M,
Baldin V, Thurieau C, Harnett J, Lanco C, Kasprzyk PG, Prevost GP, Ducommun B.
Cancer Res. 2004 May 1;64(9):3320-5.
Gemcitabine-related radiation recall preferentially involves internal tissue and
organs.
Friedlander PA, Bansal R, Schwartz L, Wagman R, Posner J, Kemeny N.
Cancer. 2004 May 1;100(9):1793-9.
New approaches to therapy of cancers of the stomach, colon and pancreas based on
peptide analogs.
Schally AV, Szepeshazi K, Nagy A, Comaru-Schally AM, Halmos G.
Cell Mol Life Sci. 2004 May;61(9):1042-68.
Therapeutic effects of systemic chemotherapy on advanced pancreatic cancer
patients
Jing Z, Nan KJ, Zhang XZ, Ruan ZP, Guo H, Xu R.
Ai Zheng. 2004 Apr;23(4):439-42.
Effects of rofecoxib on angiogenesis of pancreatic cancer xenograft in nude
mice
Zhou XC, Tang CW, Liu CL, Wang CH.
Ai Zheng. 2004 Apr;23(4):376-80.
Successful outcome after resection of pancreatic cancer with a solitary hepatic
metastasis.
Shimada K, Kosuge T, Yamamoto J, Yamasaki S, Sakamoto M.
Hepatogastroenterology. 2004 Mar-Apr;51(56):603-5.
Autocrine IL-1beta secretion leads to NF-kappabeta-mediated chemoresistance in pancreatic
carcinoma cells in vivo
Muerkoster S, Arlt A, Gehrz A, Vorndamm J, Witt M, Grohmann F, Folsch UR,
Schafer H.
Med Klin (Munich). 2004 Apr 15;99(4):185-90.
Pancreatic cancer: a major challenge in oncology
Folsch UR, Schafer H.
Med Klin (Munich). 2004 Apr 15;99(4):183-4.
Systemic chemotherapy for pancreatic cancer.
Okusaka T, Kosuge T.
Pancreas. 2004 Apr;28(3):301-4.
CEACAM6 as a novel target for indirect type 1 immunotoxin-based therapy in
pancreatic adenocarcinoma.
Duxbury MS, Ito H, Ashley SW, Whang EE.
Biochem Biophys Res Commun. 2004 May 7;317(3):837-43.
Novel therapies for pancreatic adenocarcinoma.
Pino SM, Xiong HQ, McConkey D, Abbruzzese JL.
Curr Oncol Rep. 2004 May;6(3):199-206.
Pancreatic cancer.
Li D, Xie K, Wolff R, Abbruzzese JL.
Lancet. 2004 Mar 27;363(9414):1049-57.
Assessing tumor-related signs and symptoms to support cancer drug approval.
Williams G, Pazdur R, Temple R.
J Biopharm Stat. 2004 Feb;14(1):5-21.
Pancreatic carcinoma
Bohmig M, Rosewicz S.
Z Gastroenterol. 2004 Mar;42(3):261-8
Activity of irofulven against human pancreatic carcinoma cell lines in vitro and
in vivo.
Van Laar ES, Roth S, Weitman S, MacDonald JR, Waters SJ.
Anticancer Res. 2004 Jan-Feb;24(1):59-65.
Phase I dose-finding study of biweekly irinotecan in combination with fixed
doses of 5-fluorouracil/leucovorin, gemcitabine and cisplatin (G-FLIP) in
patients with advanced pancreatic cancer or other solid tumors.
Rachamalla R, Malamud S, Grossbard ML, Mathew S, Dietrich M, Kozuch P.
Anticancer Drugs. 2004 Mar;15(3):211-7.
Treatment of advanced pancreatic cancer with opioid growth factor: phase I.
Smith JP, Conter RL, Bingaman SI, Harvey HA, Mauger DT, Ahmad M, Demers LM,
Stanley WB, McLaughlin PJ, Zagon IS.
Anticancer Drugs. 2004 Mar;15(3):203-9
Old and new drugs in systemic therapy of pancreatic cancer.
Pasetto LM, Jirillo A, Stefani M, Monfardini S.
Crit Rev Oncol Hematol. 2004 Feb;49(2):135-51.
Metastatic insulinoma: case report and review of the literature.
Tran TH, Pathak RD, Basa AL.
South Med J. 2004 Feb;97(2):199-201.
Farnesyltransferase inhibitors.
Sebti SM, Adjei AA.
Semin Oncol. 2004 Feb;31(1 Suppl 1):28-39.
Outcomes of treatment with gemcitabine for unresectable pancreatic cancer
Nobutani K, Kutsumi H, Funatsu E, Nishida K, Ikezawa S, Shiomi H, Fukiya E,
Suzuki T, Masuda K, Hata K, Nakamura H, Okuyama Y, Kimura H, Yagi N, Sugeta N,
Yashiro H, Otsuka H, Suyama Y, Fujimoto S.
Gan To Kagaku Ryoho. 2004 Feb;31(2):199-203.
In response to Li et al.: Concurrent chemoradiotherapy treatment of locally
advanced pancreatic cancer: gemcitabine versus 5-fluorouracil, a randomized
controlled study. IJROBP 2003;57:98-104.
Crane CH.
Int J Radiat Oncol Biol Phys. 2004 Mar 1;58(3):1009; author reply 1009-10.
Tumour suppression induced by the macrophage activating lipopeptide MALP-2 in an
ultrasound guided pancreatic carcinoma mouse model.
Schneider C, Schmidt T, Ziske C, Tiemann K, Lee KM, Uhlinsky V, Behrens P,
Sauerbruch T, Schmidt-Wolf IG, Muhlradt PF, Schmidt J, Marten A.
Gut. 2004 Mar;53(3):355-61.
Best supportive care of pancreatic carcinoma
Schoppmeyer K, Mossner J.
Internist (Berl). 2004 Jul;45(7):769-76.
Másodvonal alkalmazott kezelés
A phase II trial of FUdR in patients with advanced pancreatic cancer.
Ardalan B, Lima M.
J Cancer Res Clin Oncol. 2004 Oct;130(10):561-6.
Új készítmények
Emerging drugs in pancreatic cancer.
Ducreux M, Boige V, Malka D.
Expert Opin Emerg Drugs. 2004 May;9(1):73-89
Gemcitabine suppresses malignant ascites of human pancreatic cancer: correlation
with VEGF expression in ascites.
Kuwahara K, Sasaki T, Kobayashi K, Noma B, Serikawa M, Iiboshi T, Miyata H,
Kuwada Y, Murakami M, Yamasaki S, Kariya K, Morinaka K, Chayama K.
Oncol Rep. 2004 Jan;11(1):73-80.
Antiangiogenic and antitumor efficacy of EphA2 receptor antagonist.
Dobrzanski P, Hunter K, Jones-Bolin S, Chang H, Robinson C, Pritchard S, Zhao H,
Ruggeri B.
Cancer Res. 2004 Feb 1;64(3):910-9.
Celecoxib inhibits vascular endothelial growth factor expression in and reduces
angiogenesis and metastasis of human pancreatic cancer via suppression of Sp1
transcription factor activity.
Wei D, Wang L, He Y, Xiong HQ, Abbruzzese JL, Xie K.
Cancer Res. 2004 Mar 15;64(6):2030-8.
Intraarteriális chemotherápia
A devised method of hepatic and splenic arterial infusion chemotherapy after
transcatheter peripancreatic arterial embolization for patients with advanced
pancreatic cancer
Akiyama T, Homma H, Mezawa S, Takahashi S, Katsuki S, Murakami K, Kogawa K,
Hirata K.
Gan To Kagaku Ryoho. 2004 Oct;31(11):1730-2.
A case of successful management of nonresectable pancreas cancer with liver
metastasis by intra-arterial infusion chemotherapy with gemcitabine
hydrochloride, 5-FU, CDDP and administration of tegafur/uracil
Ishikawa T, Mizuno K, Watanabe K, Baba Y, Oota H, Yoshida T, Kamimura T.
Gan To Kagaku Ryoho. 2004 Oct;31(10):1555-8.
Catheter position for adequate intra-arterial chemotherapy for advanced
pancreatic cancer: evaluation with CT during arterial injection of contrast
material.
Tanaka T, Sakaguchi H, Anai H, Yamamoto K, Morimoto K, Nishiofuku H, Kichikawa
K.
J Vasc Interv Radiol. 2004 Oct;15(10):1089-97.
Balloon catheter hypoxic abdominal perfusion with Mitomycin C and Melphalan for
locally advanced pancreatic cancer: a phase I-II trial.
van IJken MG, van Etten B, Guetens G, ten Hagen TL, Jeekel J, de Bruijn EA,
Eggermont AM, van Eijck CH.
Eur J Surg Oncol. 2004 Aug;30(6):671-80.
Occlusion of central venous port catheters after simultaneous 24 h infusions of
5-FU and calcium-folinic acid in patients with gastrointestinal cancer
Fackler-Schwalbe I, Schwalbe B, Epple M, Becker A, Prugl L, Gassel WD, Stoffels
D, Sudhoff T.
Wien Med Wochenschr. 2004 May;154(9-10):182-5.
Hemodynamic variations during thoracic and abdominal stop-flow regional
chemotherapy.
Varrassi G, Guadagni S, Ciccozzi A, Marinangeli F, Pozone T, Piroli A, Marsili
I, Paladini A.
Eur J Surg Oncol. 2004 May;30(4):377-83.
Neuroendocrin tumor kezelése
The diagnosis and treatment of insulinoma and gastrinoma
Honda M, Ishibashi M.
Gan To Kagaku Ryoho. 2004 Mar;31(3):337-41.
Considerations concerning a tailored, individualized therapeutic management of
patients with (neuro)endocrine tumours of the gastrointestinal tract and
pancreas.
de Herder WW, Krenning EP, Van Eijck CH, Lamberts SW.
Endocr Relat Cancer. 2004 Mar;11(1):19-34.
Basis for treatment of functioning neuroendocrine tumours.
Tomassetti P, Migliori M, Campana D, Brocchi E, Piscitelli L, Salomone T,
Corinaldesi R.
Dig Liver Dis. 2004 Feb;36 Suppl 1:S35-41
Is lanreotide and/or interferon alfa an adequate therapy for neuroendocrine
tumors?
Volter V, Peschel C.
J Clin Oncol. 2004 Feb 1;22(3):573; author reply 574-5.
Prospective, randomized, multicenter trial on the antiproliferative effect of lanreotide,
interferon alfa, and their combination for therapy of metastatic neuroendocrine
gastroenteropancreatic tumors.
Fazio N, Oberg K.
J Clin Oncol. 2004 Feb 1;22(3):573-4; author reply 574-5.
Chemoradiotherápia
Effect of intraoperative radiotherapy combined with external beam radiotherapy
following internal drainage for advanced pancreatic carcinoma.
Ma HB, Di ZL, Wang XJ, Kang HF, Deng HC, Bai MH.
World J Gastroenterol. 2004 Jun 1;10(11):1669-771.
Phase II study of radiotherapy combined with gemcitabine for locally advanced
pancreatic cancer.
Okusaka T, Ito Y, Ueno H, Ikeda M, Takezako Y, Morizane C, Kagami Y, Ikeda H.
Br J Cancer. 2004 Aug 16;91(4):673-7.
Intensity-modulated radiotherapy (IMRT) and concurrent capecitabine for
pancreatic cancer.
Ben-Josef E, Shields AF, Vaishampayan U, Vaitkevicius V, El-Rayes BF, McDermott
P, Burmeister J, Bossenberger T, Philip PA.
Int J Radiat Oncol Biol Phys. 2004 Jun 1;59(2):454-9.
Intensity-modulated radiotherapy in treatment of pancreatic and bile duct
malignancies: toxicity and clinical outcome.
Milano MT, Chmura SJ, Garofalo MC, Rash C, Roeske JC, Connell PP, Kwon OH, Jani
AB, Heimann R.
Int J Radiat Oncol Biol Phys. 2004 Jun 1;59(2):445-53
Therapeutic effect of three-dimensional conformal radiotherapy on locally
advanced pancreatic carcinoma.
Shi YS, Xu SJ, Zheng XK, Yan WP, Chen LH.
Di Yi Jun Yi Da Xue Xue Bao. 2004 Feb;24(2):213-5, 219.
Phase II study of external irradiation and weekly paclitaxel for nonmetastatic,
unresectable pancreatic cancer: RTOG-98-12.
Rich T, Harris J, Abrams R, Erickson B, Doherty M, Paradelo J, Small W Jr,
Safran H, Wanebo HJ.
Am J Clin Oncol. 2004 Feb;27(1):51-6.
Radiochemotherapy in unresectable pancreatic cancer.
Hocht S, Wiegel T, Siegmann A, Hinkelbein W.
Front Radiat Ther Oncol. 2004;38:87-93.
5-fluorouracil-based chemoradiation in unresectable pancreatic carcinoma: Phase
I-II dose-escalation study.
Morganti AG, Valentini V, Macchia G, Mattiucci GC, Costamagna G, Deodato F,
Smaniotto D, Luzi S, Balducci M, Barbi S, Perri V, Trodella L, Cellini N.
Int J Radiat Oncol Biol Phys. 2004 Aug 1;59(5):1454-60.
Chemotherapy for pancreatic cancer.
Tsai JY, Nadeem A, Safran H.
Med Health R I. 2004 May;87(5):132-4.
Concurrent chemoradiotherapy using full-dose gemcitabine for patients with
unresectable pancreatic cancer
Yamazaki H, Nishiyama K, Koizumi M.
Nippon Igaku Hoshasen Gakkai Zasshi. 2004 May;64(4):216-9.
Intraoperativ therápia
Phase III trial of radiosensitizer PR-350 combined with intraoperative
radiotherapy for the treatment of locally advanced pancreatic cancer.
Sunamura M, Karasawa K, Okamoto A, Ogata Y, Nemoto K, Hosotani R, Nishimura Y,
Matsui K, Matsuno S; PR-350 study group.
Pancreas. 2004 Apr;28(3):330-4.
Intraoperative radiation therapy for pancreatic adenocarcinoma: the Komagome
hospital experience.
Okamoto A, Matsumoto G, Tsuruta K, Baba H, Karasawa K, Kamisawa T, Egawa N.
Pancreas. 2004 Apr;28(3):296-300
Intraoperative 125I brachytherapy combined with chemotherapy for pancreatic cancer
Wang DM, Liu YH, Yu SP, Duan XN, Yang YM, Wan YL, Zhou G, Shen WJ.
Zhonghua Zhong Liu Za Zhi. 2004 Jul;26(7):433-6.
Pancreatic liver metastases after curative resection combined with
intraoperative radiation for pancreatic cancer.
Takamori H, Hiraoka T, Kanemitsu K, Tsuji T.
Hepatogastroenterology. 2004 Sep-Oct;51(59):1500-3.
Genetica
Pancreatic carcinogenesis: apoptosis and angiogenesis.
Onizuka S, Kawakami S, Taniguchi K, Fujioka H, Miyashita K.
Pancreas. 2004 Apr;28(3):317-9.
Current status of gene therapy for pancreatic cancer.
Ramirez PJ, Vickers SM.
Curr Surg. 2004 Jan-Feb;61(1):84-92.
Current status of gene therapy for pancreatic cancer.
Ramirez PJ, Vickers SM.
Curr Surg. 2004 Jan-Feb;61(1):84-92.
